Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed Aug 11, 2021. Long positions only.
- Positions
- 46
- No 13F data for Q4 2020
- Portfolio value
- $356.8M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| OTICOtonomy, Inc. | COM | 450,000 | $1.15M | 0.3% | – | – | History |
| APVOAptevo Therapeutics Inc. | COM NEW | 50,000 | $1.53M | 0.4% | – | – | History |
| CASICASI Pharmaceuticals, Inc (DE) | COM | 650,000 | $1.56M | 0.4% | – | – | History |
| CMRXChimerix Inc | COM | 200,000 | $1.93M | 0.5% | – | – | History |
| DTILPrecision Biosciences Inc | COM | 200,000 | $2.07M | 0.6% | – | – | History |
| CTICCti Biopharma Corp | COM | 750,000 | $2.18M | 0.6% | – | – | History |
| SAGESage Therapeutics, Inc. | COM | 30,000 | $2.25M | 0.6% | – | – | History |
| KDMNKadmon Holdings, Inc. | COM | 600,000 | $2.33M | 0.7% | – | – | History |
| FOLDAmicus Therapeutics, Inc. | COM | 265,000 | $2.62M | 0.7% | – | – | History |
| NVAXNovavax Inc | COM NEW | 17,500 | $3.17M | 0.9% | – | – | History |
| SRRASierra Oncology, Inc. | COM NEW | 200,000 | $3.45M | 1.0% | – | – | History |
| IMVTImmunovant, Inc. | COM | 250,000 | $4.01M | 1.1% | – | – | History |
| IMUXImmunic, Inc. | COM | 265,000 | $4.22M | 1.2% | – | – | History |
| KYNBKyntra Bio, Inc. | COM | 125,000 | $4.34M | 1.2% | – | – | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 150,000 | $4.48M | 1.3% | – | – | History |
| CRISCuris Inc | COM NEW | 425,000 | $4.81M | 1.3% | – | – | History |
| NUVBNuvation Bio Inc. | COM CL A | 500,000 | $4.96M | 1.4% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 300,000 | $5.01M | 1.4% | – | – | History |
| GYREGyre Therapeutics, Inc. | COM NEW | 1,000,000 | $5.04M | 1.4% | – | – | History |
| EPIXESSA Pharma Inc. | COM NEW | 175,000 | $5.08M | 1.4% | – | – | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 500,000 | $5.08M | 1.4% | – | – | History |
| MLTXMoonLake Immunotherapeutics | COM CL A | 500,000 | $5.12M | 1.4% | – | – | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 904,225 | $5.14M | 1.4% | – | – | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 250,000 | $5.15M | 1.4% | – | – | History |
| BIIBBiogen Inc. | COM | 20,000 | $5.59M | 1.6% | – | – | History |
| CNSTConstellation Pharmaceuticals Inc | COM | 275,000 | $6.43M | 1.8% | – | – | History |
| iShares Russell 2000 ETF464287655 | ETF | 30,000 | $6.63M | 1.9% | – | – | – |
| ISEEIVERIC bio, Inc. | COM | 1,125,000 | $6.95M | 1.9% | – | – | History |
| MRSNMersana Therapeutics, Inc. | COM | 450,000 | $7.28M | 2.0% | – | – | History |
| ALDXAldeyra Therapeutics, Inc. | COM | 650,000 | $7.72M | 2.2% | – | – | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 939,043 | $7.85M | 2.2% | – | – | History |
| MRTXMirati Therapeutics, Inc. | COM | 50,000 | $8.56M | 2.4% | – | – | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 4,143,702 | $8.83M | 2.5% | – | – | History |
| TGTXTG Therapeutics, Inc. | COM | 200,000 | $9.64M | 2.7% | – | – | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 225,000 | $9.65M | 2.7% | – | – | History |
| ARVNArvinas, Inc. | COM | 205,000 | $13.6M | 3.8% | – | – | History |
| COGTCogent Biosciences, Inc. | COM | 1,600,000 | $14.0M | 3.9% | – | – | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 325,000 | $14.4M | 4.0% | – | – | History |
| ACRSAclaris Therapeutics, Inc. | COM | 600,000 | $15.1M | 4.2% | – | – | History |
| XENEXenon Pharmaceuticals Inc. | COM | 850,000 | $15.2M | 4.3% | – | – | History |
| FATEFate Therapeutics Inc | COM | 185,000 | $15.3M | 4.3% | – | – | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 500,000 | $15.8M | 4.4% | – | – | History |
| KURAKura Oncology, Inc. | COM | 600,000 | $17.0M | 4.8% | – | – | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 135,000 | $17.4M | 4.9% | – | – | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 1,950,000 | $20.9M | 5.9% | – | – | – |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,175,000 | $26.3M | 7.4% | – | – | History |
Options (4)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.